However, a crucial challenge for the personalized treatment approach is determining the MHC-binding potential of non-self peptides that arise from somatic tumor mutations, and determining which among them are most likely to be potent neo-antigens in a given cancer type, and given the patients repertoire of HLA alleles that encode different MHC class I receptors. This evidence concerns the gene HLA-C and cancer.